Developer docs
API playgroundTry for free, no card

Search company profiles

Archeus Technologies

Full company profile

uuid000b7ga

Namestring
Archeus Technologies
Legal namestring
Archeus Technologies
Websiteurl
archeustech.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Archeus Technologies is a clinical-stage, privately held biopharmaceutical company founded in 2016 and headquartered in Madison, Wisconsin, that develops differentiated small-molecule radiopharmaceutical therapies (RPTs) for hard-to-treat cancers. The company's pipeline is built around a proprietary NM600 tumor-targeting platform — a small-molecule chemistry platform developed through a long-standing collaboration with the University of Wisconsin-Madison — that enables selective delivery of therapeutic and diagnostic radioisotopes to tumor tissue. Its lead clinical programs include ARC-706 (a yttrium-90 radiopharmaceutical therapy designed for combination with immune checkpoint inhibitors across multiple oncology indications), ARC-166 (a yttrium-86 PET companion diagnostic for imaging-guided dosing of ARC-706), and ART-101 (a PSMA-targeting small molecule for imaging and treatment of metastatic castration-resistant prostate cancer, positioned as a differentiated alternative to FDA-approved PSMA agents with lower salivary gland uptake). The FDA cleared Investigational New Drug applications for all three programs in June 2025, and first patient dosings occurred in December 2025 (ART-101) and May 2026 (ARC-706/ARC-166).

Archeus operates a clinical-development-driven business model with no commercial revenue. The company runs Phase 1 trials through academic medical center partnerships — principally UW Carbone Cancer Center and BAMF Health, a vertically integrated theranostics platform — and co-develops its PSMA program under a collaboration with the Wisconsin Alumni Research Foundation (WARF). Its intended monetization path is licensing, royalty, and commercial sale of approved radiopharmaceutical therapies, with distribution expected through specialty pharmacies and hospital systems post-approval. The company has 1-10 employees, is led by CEO Evan Sengbusch (former president of Phoenix, sold to SHINE Technologies), and is supported by a leadership and advisory team drawn from UW-Madison faculty, former executives of Nordion, Jubilant, Plus Therapeutics, Bracco, and IBA Molecular, and the inventor of ProHance (Mike Tweedle). Multiple granted patents protect the NM600 platform and alkylphosphocholine analog chemistry, with co-founder Jamey Weichert listed as co-inventor on more than 50 patents in cancer imaging and therapy agents.

The company's strategic positioning emphasizes theranostics (paired therapeutic and diagnostic agents), combination radiotherapy-plus-immunotherapy, and improved tolerability relative to incumbent PSMA radioligands. As of mid-2026 the company is pre-revenue, with three Phase 1-enabling INDs cleared, two active Phase 1 trials, and a recently expanded clinical leadership team — typical of an early clinical-stage oncology company approximately 3-5 years from potential pivotal-stage data.

Short descriptiontext

Archeus Technologies is a clinical-stage radiopharmaceutical company developing differentiated small-molecule therapies and companion diagnostics for hard-to-treat cancers, with three FDA-cleared IND programs (ARC-706, ARC-166, ART-101) in Phase 1 trials targeting metastatic and prostate cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMadison, United States
HQ citystring
Madison
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical therapies, oncology drug development, companion diagnostics, cancer therapeutics, radiopharmaceutical agents
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceutical Oncology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Radiopharmaceutical Therapy Pipeline
TypeOne Time License
Description

Archeus Technologies is a clinical-stage company developing a pipeline of differentiated radiopharmaceutical therapy agents. Revenue will be generated through commercialization of novel cancer therapies pending regulatory approval.

archeustech.com
2Companion Diagnostics
TypeLicensing Royalties
Description

The company develops companion diagnostic assets alongside therapeutic products, enabling personalized treatment selection and dosing optimization for radiopharmaceutical therapies.

archeustech.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Archeus Technologies is a clinical-stage radiopharmaceutical company developing differentiated small-molecule radiopharmaceutical therapies (RPTs) and companion diagnostics for hard-to-treat cancers. Its pipeline includes ARC-706 (yttrium-90 therapy paired with the ARC-166 yttrium-86 PET companion diagnostic for combination use with immune checkpoint inhibitors) and ART-101 (a PSMA-targeting agent for prostate cancer), all built on the proprietary NM600 tumor-targeting platform developed through its long-standing collaboration with the University of Wisconsin-Madison.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • ARC-706 at specific dose ranges based on imaging significantly increases response rate and durability of responses to immune checkpoint inhibitor therapies in preclinical studies
+1 more record
Product overview1 text field

Archeus Technologies develops differentiated radiopharmaceutical therapies (RPTs) for hard-to-treat cancers using a theranostic approach combining therapeutic agents with companion diagnostics. The portfolio includes: ARC-706 (yttrium-90 therapeutic) with companion diagnostic ARC-166 (yttrium-86 PET imaging), and ART-101 (PSMA-targeting agent for prostate cancer). All products leverage the proprietary NM600 tumor-targeting platform technology. The company operates a clinical-stage pipeline with multiple Phase 1 trials initiated for various cancer indications.

Product and service3 records
1ARC-706
CategoryRadiopharmaceutical Therapy
Description

Small-molecule radiopharmaceutical therapy (RPT) using yttrium-90 (Y-90), a therapeutic beta-emitting isotope, leveraging the proprietary NM600 tumor-targeting platform. Developed for combination use with validated immune checkpoint inhibitor (ICI) therapies across a range of oncology indications to augment anti-tumor immune response. Currently in Phase 1 clinical development for metastatic cancer patients.

2ARC-166
CategoryCompanion Diagnostic
Description

Companion diagnostic using yttrium-86 (Y-86) PET isotope for dosimetry, patient selection, and imaging-guided dosing to determine specific dose ranges for ARC-706 therapy. Developed for oncology patient stratification and personalized treatment planning.

3ART-101
CategoryRadiopharmaceutical Therapy
Description

Novel receptor-based small-molecule radiopharmaceutical therapy targeting prostate-specific membrane antigen (PSMA) for imaging and treatment of prostate cancer. Demonstrated higher tumor uptake and retention with lower normal tissue and salivary gland uptake compared to FDA-approved PSMA-targeting agents in preclinical studies. Radiolabeled with Indium-111 for diagnostic imaging. Currently in Phase 1 development for metastatic castration-resistant prostate cancer.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-02
Description

Collaboration agreement with WARF, the designated patent and licensing organization for the University of Wisconsin–Madison. WARF provides significant development support for ART-101, the company's PSMA-targeting prostate cancer therapy. WARF Accelerator improves commercialization potential through industry engagement and proof-of-concept milestones.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-02
Description

Clinical trial partnership with BAMF Health, the world's first vertically integrated platform for intelligence-based precision medicine. BAMF serves as principal investigator site for Phase 1 clinical trial of ART-101 in metastatic castration-resistant prostate cancer patients. BAMF's nationwide platform enables rapid initiation and completion of novel clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing strategic collaboration with UW, a global leader in radiopharmaceuticals and theranostics. This partnership enables Archeus privileged access to leading radiochemistry, imaging, dosimetry, and analytical capabilities. The collaboration supports preclinical research, clinical translation, and development of the company's pipeline of radiopharmaceutical therapies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Novartis commercializes Pluvicto (177Lu-PSMA-617), the FDA-approved PSMA-targeted radioligand therapy that directly competes with Archeus's ART-101 in metastatic castration-resistant prostate cancer. Novartis also has a broader radioligand pipeline (lutathera, etc.) making it the dominant incumbent in the radiopharmaceutical oncology space Archeus targets.

TypeBroad incumbent
Description

Curium is one of the largest dedicated radiopharmaceutical manufacturers globally, supplying diagnostic and therapeutic nuclear medicine products worldwide. Comparable as an incumbent in the same end-market Archeus will ultimately sell into, with established radiopharma manufacturing and distribution capabilities.

TypeDirect peer
Description

Lantheus develops and commercializes PSMA-targeted diagnostic imaging agents (PYLARIFY) used to identify candidates for PSMA radioligand therapy. As the dominant PSMA imaging player, Lantheus is a direct comparable in the theranostic workflow that Archeus's ARC-166 companion diagnostic targets, and shares the same end-customer radiopharma centers.

TypeDirect peer
Description

RayzeBio was a clinical-stage radiopharmaceutical company developing actinium-225-based radiopharmaceuticals for solid tumors, acquired by BMS in early 2024 for $4.1B. Closely comparable to Archeus in stage, approach (targeted radionuclide therapy), and likely exit trajectory as a strategic acquisition target.

TypeDirect peer
Description

Point Biopharma was a clinical-stage radiopharmaceutical company developing PSMA-targeted and other radioligand therapies, acquired by Lilly in 2023 for $1.4B. It represents the most direct comparable to Archeus's stage and approach, validating the M&A appetite for clinical-stage radiopharma assets while raising the competitive bar.

TypeBroad incumbent
Description

Bayer commercializes Xofigo (radium-223), the first approved alpha-emitting radiopharmaceutical for prostate cancer, and has ongoing radioligand therapy development through its broader pharma portfolio. As a large incumbent with established radiopharma manufacturing and commercial reach, Bayer represents the scale player Archeus would need to partner with or compete against.

TypeDirect peer
Description

Plus Therapeutics is a clinical-stage radiopharmaceutical company developing targeted radiotherapies for CNS cancers and other solid tumors. Particularly relevant as Norman LaFrance, Archeus's Chair of Advisory Board, was previously Plus's CMO — and Plus's smaller, late-clinical-stage profile is a realistic comp for Archeus's likely trajectory.

TypeDirect peer
Description

Telix is a commercial-stage radiopharmaceutical company with approved PSMA imaging agent Illuccix and a broad theranostic pipeline across prostate cancer, renal cell carcinoma, and other solid tumors. Comparable to Archeus as a radiopharma-focused oncology company pursuing paired imaging/therapy strategies.

TypeDirect peer
Description

Fusion was a clinical-stage radioconjugate company developing targeted alpha therapies, acquired by AstraZeneca in 2024 for $2.4B. Comparable to Archeus in combining targeting platforms with therapeutic radioisotopes, and another data point on big-pharma M&A appetite for clinical-stage radiopharma platforms.

TypeEmerging player
Description

ITM is a privately held radiopharmaceutical company developing targeted radionuclide therapies (notably ITM-11, a 177Lu-Edotreotide PRRT candidate) and producing medical radioisotopes. Comparable as a similarly-sized clinical-stage radiopharma company pursuing theranostic approaches across multiple oncology indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Archeus Technologies

Radiopharmaceutical Oncology Therapeuticsarcheustech.com

Archeus Technologies is a clinical-stage radiopharmaceutical company developing differentiated small-molecule therapies and companion diagnostics for hard-to-treat cancers, with three FDA-cleared IND programs (ARC-706, ARC-166, ART-101) in Phase 1 trials targeting metastatic and prostate cancers.

What Archeus Technologies does

Archeus Technologies is a clinical-stage, privately held biopharmaceutical company founded in 2016 and headquartered in Madison, Wisconsin, that develops differentiated small-molecule radiopharmaceutical therapies (RPTs) for hard-to-treat cancers. The company's pipeline is built around a proprietary NM600 tumor-targeting platform — a small-molecule chemistry platform developed through a long-standing collaboration with the University of Wisconsin-Madison — that enables selective delivery of therapeutic and diagnostic radioisotopes to tumor tissue. Its lead clinical programs include ARC-706 (a yttrium-90 radiopharmaceutical therapy designed for combination with immune checkpoint inhibitors across multiple oncology indications), ARC-166 (a yttrium-86 PET companion diagnostic for imaging-guided dosing of ARC-706), and ART-101 (a PSMA-targeting small molecule for imaging and treatment of metastatic castration-resistant prostate cancer, positioned as a differentiated alternative to FDA-approved PSMA agents with lower salivary gland uptake). The FDA cleared Investigational New Drug applications for all three programs in June 2025, and first patient dosings occurred in December 2025 (ART-101) and May 2026 (ARC-706/ARC-166).

Archeus operates a clinical-development-driven business model with no commercial revenue. The company runs Phase 1 trials through academic medical center partnerships — principally UW Carbone Cancer Center and BAMF Health, a vertically integrated theranostics platform — and co-develops its PSMA program under a collaboration with the Wisconsin Alumni Research Foundation (WARF). Its intended monetization path is licensing, royalty, and commercial sale of approved radiopharmaceutical therapies, with distribution expected through specialty pharmacies and hospital systems post-approval. The company has 1-10 employees, is led by CEO Evan Sengbusch (former president of Phoenix, sold to SHINE Technologies), and is supported by a leadership and advisory team drawn from UW-Madison faculty, former executives of Nordion, Jubilant, Plus Therapeutics, Bracco, and IBA Molecular, and the inventor of ProHance (Mike Tweedle). Multiple granted patents protect the NM600 platform and alkylphosphocholine analog chemistry, with co-founder Jamey Weichert listed as co-inventor on more than 50 patents in cancer imaging and therapy agents.

The company's strategic positioning emphasizes theranostics (paired therapeutic and diagnostic agents), combination radiotherapy-plus-immunotherapy, and improved tolerability relative to incumbent PSMA radioligands. As of mid-2026 the company is pre-revenue, with three Phase 1-enabling INDs cleared, two active Phase 1 trials, and a recently expanded clinical leadership team — typical of an early clinical-stage oncology company approximately 3-5 years from potential pivotal-stage data.

Archeus Technologies firmographics

Firmographics
Name
Archeus Technologies
Legal name
Archeus Technologies
Website
https://archeustech.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Archeus Technologies is a clinical-stage radiopharmaceutical company developing differentiated small-molecule therapies and companion diagnostics for hard-to-treat cancers, with three FDA-cleared IND programs (ARC-706, ARC-166, ART-101) in Phase 1 trials targeting metastatic and prostate cancers.
Ownership category
akta.pro rank

Archeus Technologies industry classification

Industry
Product category
Radiopharmaceutical Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Radiopharmaceutical therapies
  • Oncology drug development
  • Companion diagnostics
  • Cancer therapeutics
  • Radiopharmaceutical agents

Where Archeus Technologies is headquartered

Location

Headquarters

HQ city
Madison
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Archeus Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Radiopharmaceutical Therapy Pipeline: Archeus Technologies is a clinical-stage company developing a pipeline of differentiated radiopharmaceutical therapy agents. Revenue will be generated through commercialization of novel cancer therapies pending regulatory approval.
  2. Companion Diagnostics: The company develops companion diagnostic assets alongside therapeutic products, enabling personalized treatment selection and dosing optimization for radiopharmaceutical therapies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Archeus Technologies product offering

Product offering

Core offering

Archeus Technologies is a clinical-stage radiopharmaceutical company developing differentiated small-molecule radiopharmaceutical therapies (RPTs) and companion diagnostics for hard-to-treat cancers. Its pipeline includes ARC-706 (yttrium-90 therapy paired with the ARC-166 yttrium-86 PET companion diagnostic for combination use with immune checkpoint inhibitors) and ART-101 (a PSMA-targeting agent for prostate cancer), all built on the proprietary NM600 tumor-targeting platform developed through its long-standing collaboration with the University of Wisconsin-Madison.

Product overview

Archeus Technologies develops differentiated radiopharmaceutical therapies (RPTs) for hard-to-treat cancers using a theranostic approach combining therapeutic agents with companion diagnostics. The portfolio includes: ARC-706 (yttrium-90 therapeutic) with companion diagnostic ARC-166 (yttrium-86 PET imaging), and ART-101 (PSMA-targeting agent for prostate cancer). All products leverage the proprietary NM600 tumor-targeting platform technology. The company operates a clinical-stage pipeline with multiple Phase 1 trials initiated for various cancer indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • ARC-706 Small-molecule radiopharmaceutical therapy (RPT) using yttrium-90 (Y-90), a therapeutic beta-emitting isotope, leveraging the proprietary NM600 tumor-targeting platform. Developed for combination use with validated immune checkpoint inhibitor (ICI) therapies across a range of oncology indications to augment anti-tumor immune response. Currently in Phase 1 clinical development for metastatic cancer patients.
  • ARC-166 Companion diagnostic using yttrium-86 (Y-86) PET isotope for dosimetry, patient selection, and imaging-guided dosing to determine specific dose ranges for ARC-706 therapy. Developed for oncology patient stratification and personalized treatment planning.
  • ART-101 Novel receptor-based small-molecule radiopharmaceutical therapy targeting prostate-specific membrane antigen (PSMA) for imaging and treatment of prostate cancer. Demonstrated higher tumor uptake and retention with lower normal tissue and salivary gland uptake compared to FDA-approved PSMA-targeting agents in preclinical studies. Radiolabeled with Indium-111 for diagnostic imaging. Currently in Phase 1 development for metastatic castration-resistant prostate cancer.

Quantifiable outcome

  • ARC-706 at specific dose ranges based on imaging significantly increases response rate and durability of responses to immune checkpoint inhibitor therapies in preclinical studies
  • +1 more outcomes

Companies that use Archeus Technologies

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Archeus Technologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Archeus Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and major.

  • Wisconsin Alumni Research Foundation (WARF)coreStrategic or Co-development Partner · 2 December 2025Collaboration agreement with WARF, the designated patent and licensing organization for the University of Wisconsin–Madison. WARF provides significant development support for ART-101, the company's PSMA-targeting prostate cancer therapy. WARF Accelerator improves commercialization potential through industry engagement and proof-of-concept milestones.
  • BAMF HealthmajorStrategic or Co-development Partner · 2 December 2025Clinical trial partnership with BAMF Health, the world's first vertically integrated platform for intelligence-based precision medicine. BAMF serves as principal investigator site for Phase 1 clinical trial of ART-101 in metastatic castration-resistant prostate cancer patients. BAMF's nationwide platform enables rapid initiation and completion of novel clinical trials.
  • University of Wisconsin–Madison (UW)coreStrategic or Co-development PartnerLong-standing strategic collaboration with UW, a global leader in radiopharmaceuticals and theranostics. This partnership enables Archeus privileged access to leading radiochemistry, imaging, dosimetry, and analytical capabilities. The collaboration supports preclinical research, clinical translation, and development of the company's pipeline of radiopharmaceutical therapies.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Archeus Technologies competitors and assessment

Company assessment

Direct peers

  • Novartis: Novartis commercializes Pluvicto (177Lu-PSMA-617), the FDA-approved PSMA-targeted radioligand therapy that directly competes with Archeus's ART-101 in metastatic castration-resistant prostate cancer. Novartis also has a broader radioligand pipeline (lutathera, etc.) making it the dominant incumbent in the radiopharmaceutical oncology space Archeus targets.
  • Lantheus Holdings: Lantheus develops and commercializes PSMA-targeted diagnostic imaging agents (PYLARIFY) used to identify candidates for PSMA radioligand therapy. As the dominant PSMA imaging player, Lantheus is a direct comparable in the theranostic workflow that Archeus's ARC-166 companion diagnostic targets, and shares the same end-customer radiopharma centers.
  • RayzeBio (acquired by Bristol Myers Squibb): RayzeBio was a clinical-stage radiopharmaceutical company developing actinium-225-based radiopharmaceuticals for solid tumors, acquired by BMS in early 2024 for $4.1B. Closely comparable to Archeus in stage, approach (targeted radionuclide therapy), and likely exit trajectory as a strategic acquisition target.
  • Point Biopharma (acquired by Eli Lilly): Point Biopharma was a clinical-stage radiopharmaceutical company developing PSMA-targeted and other radioligand therapies, acquired by Lilly in 2023 for $1.4B. It represents the most direct comparable to Archeus's stage and approach, validating the M&A appetite for clinical-stage radiopharma assets while raising the competitive bar.
  • Plus Therapeutics: Plus Therapeutics is a clinical-stage radiopharmaceutical company developing targeted radiotherapies for CNS cancers and other solid tumors. Particularly relevant as Norman LaFrance, Archeus's Chair of Advisory Board, was previously Plus's CMO — and Plus's smaller, late-clinical-stage profile is a realistic comp for Archeus's likely trajectory.
  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with approved PSMA imaging agent Illuccix and a broad theranostic pipeline across prostate cancer, renal cell carcinoma, and other solid tumors. Comparable to Archeus as a radiopharma-focused oncology company pursuing paired imaging/therapy strategies.
  • Fusion Pharmaceuticals (acquired by AstraZeneca): Fusion was a clinical-stage radioconjugate company developing targeted alpha therapies, acquired by AstraZeneca in 2024 for $2.4B. Comparable to Archeus in combining targeting platforms with therapeutic radioisotopes, and another data point on big-pharma M&A appetite for clinical-stage radiopharma platforms.

Broad incumbents

  • Curium: Curium is one of the largest dedicated radiopharmaceutical manufacturers globally, supplying diagnostic and therapeutic nuclear medicine products worldwide. Comparable as an incumbent in the same end-market Archeus will ultimately sell into, with established radiopharma manufacturing and distribution capabilities.
  • Bayer: Bayer commercializes Xofigo (radium-223), the first approved alpha-emitting radiopharmaceutical for prostate cancer, and has ongoing radioligand therapy development through its broader pharma portfolio. As a large incumbent with established radiopharma manufacturing and commercial reach, Bayer represents the scale player Archeus would need to partner with or compete against.

Emerging players

  • ITM Isotope Technologies: ITM is a privately held radiopharmaceutical company developing targeted radionuclide therapies (notably ITM-11, a 177Lu-Edotreotide PRRT candidate) and producing medical radioisotopes. Comparable as a similarly-sized clinical-stage radiopharma company pursuing theranostic approaches across multiple oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Archeus Technologies social profiles

Digital presence

Archeus Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Archeus Technologies leadership team

Management profile

Number of profiles

Profiles12 records

Archeus Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Archeus Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Archeus Technologies

What does Archeus Technologies do?

Archeus Technologies is a clinical-stage radiopharmaceutical company developing differentiated small-molecule radiopharmaceutical therapies (RPTs) and companion diagnostics for hard-to-treat cancers. Its pipeline includes ARC-706 (yttrium-90 therapy paired with the ARC-166 yttrium-86 PET companion diagnostic for combination use with immune checkpoint inhibitors) and ART-101 (a PSMA-targeting agent for prostate cancer), all built on the proprietary NM600 tumor-targeting platform developed through its long-standing collaboration with the University of Wisconsin-Madison.

Is Archeus Technologies a public or private company?

Archeus Technologies is a private company. It is classified as unknown and is currently operating.

When was Archeus Technologies founded?

Archeus Technologies was founded in 2016. It employs 1 to 10 people.

Where is Archeus Technologies based?

Archeus Technologies is headquartered in Madison, United States, in the North America region.

How does Archeus Technologies make money?

Two revenue lines are on record. Radiopharmaceutical Therapy Pipeline is the primary driver. The others are companion Diagnostics.

Who are Archeus Technologies's main competitors?

Direct peers on record are Novartis, Lantheus Holdings, RayzeBio (acquired by Bristol Myers Squibb), Point Biopharma (acquired by Eli Lilly), Plus Therapeutics, Telix Pharmaceuticals and Fusion Pharmaceuticals (acquired by AstraZeneca). Broad incumbents are Curium and Bayer. ITM Isotope Technologies is listed as an emerging player.

Does Archeus Technologies have an API?

No public API is recorded for Archeus Technologies.

What industry is Archeus Technologies in?

Archeus Technologies's product category is Radiopharmaceutical Oncology Therapeutics. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceArcheus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic CancerArcheus Technologies has dosed the first patient in a Phase 1 clinical trial of ARC-706, a small-molecule radiopharmaceutical therapy using yttrium-90, along with its companion diagnostic ARC-166, in patients with metastatic cancer receiving immune checkpoint inhibition therapies. The first-in-human study will evaluate safety, biodistribution, pharmacokinetics, and the therapy's potential to augment anti-tumor immune response, with plans to determine an optimal Phase 1b dose. Preclinical studies demonstrated that administering ARC-706 at specific dose ranges based on ARC-166 imaging results can significantly increase response rates and durability of responses to ICI therapies.Business Wire BlogArcheus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic CancerArcheus Technologies dosed the first patient in a Phase 1 trial of ARC-706 and companion diagnostic ARC-166 for metastatic cancer patients receiving immune checkpoint inhibitors. The study evaluates safety, biodistribution, and potential to augment anti-tumor immune response, aiming to determine an optimal Phase 1b dose.AuntMinnieArcheus Technologies names new slate of executivesArcheus Technologies, a Madison, Wisconsin-based radiopharmaceutical therapy developer, has appointed a new executive leadership team including Reinier Hernandez as chief technology officer and Zachary Morris as chief medical officer. The company also named Norman LaFrance as chair of its advisory board and Bruce D. Berndt to its board of directors. According to CEO Evan Sengbusch, these appointments are designed to strengthen the organization as it advances multiple clinical trials for novel radiopharmaceutical therapies targeting various cancer indications.